Sana Biotechnology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sana Biotechnology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-11.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 53% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-9.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
52%Of every $100 the company owns, $52 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 80% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Sana Biotechnology, Inc. made a loss over the last year. Sana Biotechnology, Inc. owes $0.64 for every $1 it owns. Sana Biotechnology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSana Biotechnology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.51The share price is 4.51 times Sana Biotechnology, Inc.'s book value per share, higher than 69% of Healthcare companies in United States.
Market cap
$698 MThe total market value of all of Sana Biotechnology, Inc.'s shares at today's price (share price × number of shares), larger than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$155 MWhat Sana Biotechnology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.52Net worth divided by the number of shares. The share price of $2.33 is 4.5 times this, which is the P/B above.
Return on equity (ROE)
-152.9%Sana Biotechnology, Inc. lost 152.9% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
Owes vs Owns
0.64×Sana Biotechnology, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Dividend yield
NoneSana Biotechnology, Inc. does not currently pay a dividend.
Profit growth
LossSana Biotechnology, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSana Biotechnology, Inc. held $60 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sana Biotechnology, Inc.: $698 M ÷ $155 M (30 Jun 2026) = 4.5.
What is Sana Biotechnology, Inc.'s return on equity?
Sana Biotechnology, Inc. lost 152.9% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
How much does Sana Biotechnology, Inc. owe compared with what it owns?
Sana Biotechnology, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Does Sana Biotechnology, Inc. pay a dividend?
No. Sana Biotechnology, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.